Literature DB >> 25616278

Serum proteomes distinguish children developing type 1 diabetes in a cohort with HLA-conferred susceptibility.

Robert Moulder1, Santosh D Bhosale1, Timo Erkkilä2, Essi Laajala1, Jussi Salmi1, Elizabeth V Nguyen1, Henna Kallionpää1, Juha Mykkänen3, Mari Vähä-Mäkilä3, Heikki Hyöty4, Riitta Veijola5, Jorma Ilonen6, Tuula Simell3, Jorma Toppari7, Mikael Knip8, David R Goodlett9, Harri Lähdesmäki10, Olli Simell3, Riitta Lahesmaa11.   

Abstract

We determined longitudinal serum proteomics profiles from children with HLA-conferred diabetes susceptibility to identify changes that could be detected before seroconversion and positivity for disease-associated autoantibodies. Comparisons were made between children who seroconverted and progressed to type 1 diabetes (progressors) and those who remained autoantibody negative, matched by age, sex, sample periodicity, and risk group. The samples represented the prediabetic period and ranged from the age of 3 months to 12 years. After immunoaffinity depletion of the most abundant serum proteins, isobaric tags for relative and absolute quantification were used for sample labeling. Quantitative proteomic profiles were then measured for 13 case-control pairs by high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS). Additionally, a label-free LC-MS/MS approach was used to analyze depleted sera from six case-control pairs. Importantly, differences in abundance of a set of proteins were consistently detected before the appearance of autoantibodies in the progressors. Based on top-scoring pairs analysis, classification of such progressors was observed with a high success rate. Overall, the data provide a reference of temporal changes in the serum proteome in healthy children and children progressing to type 1 diabetes, including new protein candidates, the levels of which change before clinical diagnosis.
© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25616278     DOI: 10.2337/db14-0983

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  13 in total

Review 1.  Blood-based signatures in type 1 diabetes.

Authors:  Susanne M Cabrera; Yi-Guang Chen; William A Hagopian; Martin J Hessner
Journal:  Diabetologia       Date:  2015-12-23       Impact factor: 10.122

2.  The role of proteomics in assessing beta-cell dysfunction and death in type 1 diabetes.

Authors:  Ernesto S Nakayasu; Wei-Jun Qian; Carmella Evans-Molina; Raghavendra G Mirmira; Decio L Eizirik; Thomas O Metz
Journal:  Expert Rev Proteomics       Date:  2019-06-24       Impact factor: 3.940

3.  Peptide serum markers in islet autoantibody-positive children.

Authors:  Christine von Toerne; Michael Laimighofer; Peter Achenbach; Andreas Beyerlein; Tonia de Las Heras Gala; Jan Krumsiek; Fabian J Theis; Anette G Ziegler; Stefanie M Hauck
Journal:  Diabetologia       Date:  2016-11-04       Impact factor: 10.122

4.  Identification of Hip BMD Loss and Fracture Risk Markers Through Population-Based Serum Proteomics.

Authors:  Carrie M Nielson; Jack Wiedrick; Jian Shen; Jon Jacobs; Erin S Baker; Aaron Baraff; Paul Piehowski; Christine G Lee; Arie Baratt; Vladislav Petyuk; Shannon McWeeney; Jeong Youn Lim; Douglas C Bauer; Nancy E Lane; Peggy M Cawthon; Richard D Smith; Jodi Lapidus; Eric S Orwoll
Journal:  J Bone Miner Res       Date:  2017-04-06       Impact factor: 6.741

5.  Temporal profiles of plasma proteome during childhood development.

Authors:  Chih-Wei Liu; Lisa Bramer; Bobbie-Jo Webb-Robertson; Kathleen Waugh; Marian J Rewers; Qibin Zhang
Journal:  J Proteomics       Date:  2016-11-23       Impact factor: 4.044

6.  Longitudinal proteomics analysis in the immediate microenvironment of islet allografts during progression of rejection.

Authors:  Oscar Alcazar; Luis F Hernandez; Ernesto S Nakayasu; Paul D Piehowski; Charles Ansong; Midhat H Abdulreda; Peter Buchwald
Journal:  J Proteomics       Date:  2020-05-20       Impact factor: 4.044

Review 7.  Early life origin of type 1 diabetes.

Authors:  Mikael Knip; Kristiina Luopajärvi; Taina Härkönen
Journal:  Semin Immunopathol       Date:  2017-11-23       Impact factor: 9.623

Review 8.  Serum biomarkers for diagnosis and prediction of type 1 diabetes.

Authors:  Lian Yi; Adam C Swensen; Wei-Jun Qian
Journal:  Transl Res       Date:  2018-08-01       Impact factor: 7.012

9.  Temporal expression profiling of plasma proteins reveals oxidative stress in early stages of Type 1 Diabetes progression.

Authors:  Chih-Wei Liu; Lisa Bramer; Bobbie-Jo Webb-Robertson; Kathleen Waugh; Marian J Rewers; Qibin Zhang
Journal:  J Proteomics       Date:  2017-10-07       Impact factor: 4.044

Review 10.  Immunological biomarkers for the development and progression of type 1 diabetes.

Authors:  Chantal Mathieu; Riitta Lahesmaa; Ezio Bonifacio; Peter Achenbach; Timothy Tree
Journal:  Diabetologia       Date:  2018-09-12       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.